SHAPE is a novel topical HDAC inhibitor in development for CTCL

SMAC Mimetics are promising new anti-cancer therapeutics that activate cancer cell death

Birinapant is one of the most clinically advanced SMAC Mimetics for cancer

Welcome to TetraLogic Pharmaceuticals

TetraLogic is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases. Birinapant is currently being tested in Phase 1 and Phase 2 clinical trials for hematological malignancies and solid tumors. We intend to start a Phase 1 clinical trial with birinapant in Hepatitis B later this year. SHAPE (suberohydroxamic acid phenyl ester) is a novel topical HDAC inhibitor designed to maximize HDAC inhibition in the skin but limit systemic exposure. We intend to start a randomized Phase 2 clinical trial of SHAPE in early-stage Cutaneous T-Cell Lymphoma later this year.